journal article·2023-09-26Open access

Tuning DNA Dissociation from Spherical Nucleic Acids for Enhanced Immunostimulation

Jasper W. Dittmar, Michelle H. Teplensky, Michael Evangelopoulos, Lei Qin, Bin Zhang, Chad A. Mirkin

ACS Nano· Volume 17· Issue 18

Abstract

The stability of the core can significantly impact the therapeutic effectiveness of liposome-based drugs. While the spherical nucleic acid (SNA) architecture has elevated liposomal stability to increase therapeutic efficacy, the chemistry used to anchor the DNA to the liposome core is an underexplored design parameter with a potentially widespread biological impact. Herein, we explore the impact of SNA anchoring chemistry on immunotherapeutic function by systematically studying the importance of hydrophobic dodecane anchoring groups in attaching DNA strands to the liposome core. By deliberately modulating the size of the oligomer that defines the anchor, a library of structures has been established. These structures, combined with in vitro and in vivo immune stimulation analyses, elucidate the relationships between and importance of anchoring strength and dissociation of DNA from the SNA shell on its biological properties. Importantly, the most stable dodecane anchor, (C12) 9, is superior to the n = 4–8 and 10 structures and quadruples immune stimulation compared to conventional cholesterol-anchored SNAs. When the OVA1 peptide antigen is encapsulated by the (C12) 9 SNA and used as a therapeutic vaccine in an E.G7-OVA tumor model, 50% of the mice survived the initial tumor, and all of those survived tumor rechallenge. Importantly, the strong innate immune stimulation does not cause a cytokine storm compared to linear immunostimulatory DNA. Moreover, a (C12) 9 SNA that encapsulates a peptide targeting SARS-CoV-2 generates a robust T cell response; T cells raised from SNA treatment kill >40% of target cells pulsed with the same peptide and ca. 45% of target cells expressing the entire spike protein. This work highlights the importance of using anchor chemistry to elevate SNA stability to achieve more potent and safer immunotherapeutics in the context of both cancer and infectious disease.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States

Department of Chemistry and International Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States

Department of Medicine, Division of Hematology and Oncology, Northwestern University, 420 E Superior Street, Chicago, Illinois 60611, United States

Funding

National Cancer Institute · International Institute for Nanotechnology, Northwestern University · Division of Electrical, Communications and Cyber Systems · Northwestern University · Alexander S. Onassis Public Benefit Foundation · State of Illinois

References (46)

Show source-provided references
1. 10.1016/j.tips.2009.08.00410.1016/j.tips.2009.08.004 ↗
2. 10.3390/pharmaceutics902001210.3390/pharmaceutics9020012 ↗
3. 10.1038/1171010.1038/11710 ↗
4. 10.1038/382607a010.1038/382607a0 ↗
5. 10.1021/acsnano.9b0725410.1021/acsnano.9b07254 ↗
6. 10.1021/ja504845f10.1021/ja504845f ↗
7. 10.1126/science.112555910.1126/science.1125559 ↗
8. 10.1021/nl802958f10.1021/nl802958f ↗
9. 10.1021/ja052255o10.1021/ja052255o ↗
10. Intratumoral AST-008 Combined With Pembrolizumab or Cemiplimab in Patients With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT03684785 (accessed March 14, 2020).
11. A Study of AST-008 in Healthy Subjects. https://clinicaltrials.gov/ct2/show/NCT03086278 (accessed March 14, 2020).
12. 10.1126/scitranslmed.abb394510.1126/scitranslmed.abb3945 ↗
13. 10.1002/adhm.20210126210.1002/adhm.202101262 ↗
14. 10.1073/pnas.190280511610.1073/pnas.1902805116 ↗
15. 10.1021/acscentsci.1c0077910.1021/acscentsci.1c00779 ↗
16. 10.1038/s41551-022-01000-210.1038/s41551-022-01000-2 ↗
17. 10.1038/s41551-019-0351-110.1038/s41551-019-0351-1 ↗
18. 10.1021/acscentsci.1c0018110.1021/acscentsci.1c00181 ↗
19. 10.1002/smll.20170290910.1002/smll.201702909 ↗
20. 10.1038/374546a010.1038/374546a0 ↗
21. 10.1021/ja048514b10.1021/ja048514b ↗
22. 10.1021/ja043299k10.1021/ja043299k ↗
23. 10.1021/nl072471q10.1021/nl072471q ↗
24. 10.1021/jacs.9b0427210.1021/jacs.9b04272 ↗
25. Kragh-Hansen U. · Dan Med. Bull. · 1990 · 37 · 57
26. 10.1016/S0022-2275(20)36723-710.1016/S0022-2275(20)36723-7 ↗
27. 10.1073/pnas.150285011210.1073/pnas.1502850112 ↗
28. 10.4049/jimmunol.165.12.688910.4049/jimmunol.165.12.6889 ↗
29. 10.4049/jimmunol.160.4.183110.4049/jimmunol.160.4.1831 ↗
30. 10.1016/S0092-8674(88)91043-410.1016/S0092-8674(88)91043-4 ↗
31. 10.1038/nm98710.1038/nm987 ↗
32. 10.4049/jimmunol.162.4.236810.4049/jimmunol.162.4.2368 ↗
33. 10.1038/nbt0508-484a10.1038/nbt0508-484a ↗
34. 10.1002/eji.183027071210.1002/eji.1830270712 ↗
35. 10.1038/386336a010.1038/386336a0 ↗
36. 10.1007/s00281-017-0636-y10.1007/s00281-017-0636-y ↗
37. 10.1038/s41591-021-01500-910.1038/s41591-021-01500-9 ↗
38. 10.1038/s41577-020-0305-610.1038/s41577-020-0305-6 ↗
39. 10.1186/1471-2172-10-6110.1186/1471-2172-10-61 ↗
40. 10.1126/science.abi622610.1126/science.abi6226 ↗
41. 10.1038/s41467-021-27350-010.1038/s41467-021-27350-0 ↗
42. 10.1126/science.abi799410.1126/science.abi7994 ↗
43. 10.1038/s41586-022-04466-x10.1038/s41586-022-04466-x ↗
44. 10.4049/jimmunol.156.7.247310.4049/jimmunol.156.7.2473 ↗
45. 10.1002/j.1460-2075.1986.tb04307.x10.1002/j.1460-2075.1986.tb04307.x ↗
46. 10.1007/BF0037537610.1007/BF00375376 ↗